Eosinophilia Diagnosis and Management

Definition and Classification

The American College of Physicians defines eosinophilia as a peripheral blood eosinophil count >0.5 × 10⁹/L, with helminthic infections being the most common identifiable cause in travelers and migrants (19-80% of cases), followed by allergic/atopic disorders representing approximately 80% of cases in non-exposed populations 1, 2

Helminths are the most important cause in travelers and migrants, with diagnosis rates of 19-80% 1, 2
Relevant helminthic infections include Strongyloides stercoralis, which can persist for life and cause hyperinfection syndrome with high mortality in immunocompromised individuals, even >50 years after exposure 3, 2
Other helminths, such as Schistosomiasis, Filariasis, Ankylostoma, Ascaris lumbricoides, Trichuris trichiura, and Oncocercosis, can also cause eosinophilia 1, 2, 3, 4

A detailed geographic and exposure history is crucial, including exact times of possible exposures, such as swimming in freshwater lakes in Africa, walking barefoot, water consumption, and food (salads, raw fish) 3, 2
Key points to investigate include area visited, time since exposure, and patient group, as migrants tend to have a higher infection burden and travelers have a more pronounced immune response with marked eosinophilia 2
First-line laboratory tests for asymptomatic eosinophilia include concentrated stool microscopy and serology for Strongyloides in all patients 1, 2

Empiric treatment for asymptomatic eosinophilia in patients >24 months with suspected helminthic infection is albendazole 400 mg single dose PLUS ivermectin 200 μg/kg single dose 1, 2
Specific treatments for helminths include albendazole for Ankylostoma, ivermectin for Strongyloides, and praziquantel for Schistosomiasis 2, 1, 5

Any patient with eosinophilia and evidence of end-organ damage requires urgent medical evaluation and consideration of emergency treatment 1, 2
Persistent eosinophilia, especially at high levels (>1.5 × 10⁹/L), can cause significant end-organ damage affecting the heart, lungs, central nervous system, and skin 1, 2, 4

If eosinophilia persists ≥1.5 × 10⁹/L for more than 3 months without an identified cause after treatment or exclusion of infectious causes, refer to hematology for further investigation 1, 2
Monitor eosinophil counts after treatment to confirm resolution 2

The American Academy of Allergy, Asthma, and Immunology recommends that allergic rhinitis may benefit from nasal corticosteroids, which can reduce eosinophilia in both nasal tissue and peripheral blood 6

The European Academy of Allergy and Clinical Immunology suggests that antihistamines may be used for symptomatic relief of allergic symptoms but do not treat eosinophilia itself 7, 8
The American Gastroenterological Association recommends that montelukast is NOT recommended for managing eosinophilia, as it has no proven efficacy for reducing eosinophil counts or treating eosinophilic conditions 9, 7, 8, 10
The American College of Gastroenterology states that montelukast showed no benefit in reducing eosinophilia in controlled trials (OR 0.48, 95% CI 0.10-2.16, p=0.33) 7, 8
The European Society of Gastrointestinal Endoscopy notes that cromolyn sodium demonstrated minimal efficacy, with only 1 of 16 patients achieving remission in trials 9, 10
The American Academy of Allergy, Asthma, and Immunology advises that anti-IgE therapy (omalizumab) is not recommended for eosinophilia management, as it showed no effect on eosinophil counts in controlled trials 9, 10